Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders

Michelle C. Potter, Mariana Figuera-Losada, Camilo Rojas, Barbara S. Slusher

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The accumulation of excess glutamate in the extracellular space as a consequence of CNS trauma, neurodegenerative diseases, infection, or deregulation of glutamate clearance results in neuronal damage by excessive excitatory neurotransmission. Glutamate excitotoxicity is thought to be one of several mechanisms by which HIV exerts neurotoxicity that culminates in HIV-associated neurocognitive disorders (HAND). Excess glutamate is released upon HIV infection of macrophage/microglial cells and has been associated with neurotoxicity mediated by gp120, transactivator of transcription (Tat) and other HIV proteins. Several strategies have been used over the years to try to prevent glutamate excitotoxicity. Since the main toxic effects of excess glutamate are thought to be due to excitotoxicity from over activation of glutamate receptors, antagonists of these receptors have been popular therapeutic targets. Early work to ameliorate the effects of excess extracellular glutamate focused on NMDA receptor antagonism, but unfortunately, potent blockade of this receptor has been fraught with side effects. One alternative to direct receptor blockade has been the inhibition of enzymes responsible for the production of glutamate such as glutaminase and glutamate carboxypeptidase II. Another approach has been to regulate the transporters responsible for modulation of extracellular glutamate such as excitatory amino acid transporters and the glutamate-cystine antiporter. There is preliminary experimental evidence that these approaches have potential therapeutic utility for the treatment of HAND. These efforts however, are at an early stage where the next steps are dependent on the identification of drug-like inhibitors as well as the development of predictive neuroAIDS animal models.

Original languageEnglish (US)
Pages (from-to)594-607
Number of pages14
JournalJournal of NeuroImmune Pharmacology
Volume8
Issue number3
DOIs
StatePublished - Jun 2013
Externally publishedYes

Fingerprint

Glutamic Acid
HIV
Glutamate Carboxypeptidase II
Neurocognitive Disorders
Glutaminase
Human Immunodeficiency Virus Proteins
Antiporters
Amino Acid Transport Systems
Excitatory Amino Acid Antagonists
Excitatory Amino Acids
Trans-Activators
Cystine
Poisons
Extracellular Space
N-Methyl-D-Aspartate Receptors
Synaptic Transmission
Neurodegenerative Diseases
HIV Infections
Animal Models
Macrophages

Keywords

  • Excitotoxicity
  • Glutamate
  • Glutamate carboxypeptidase II
  • Glutaminase
  • HIV-associated neurocognitive disorder

ASJC Scopus subject areas

  • Pharmacology
  • Immunology and Allergy
  • Immunology
  • Neuroscience (miscellaneous)

Cite this

Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders. / Potter, Michelle C.; Figuera-Losada, Mariana; Rojas, Camilo; Slusher, Barbara S.

In: Journal of NeuroImmune Pharmacology, Vol. 8, No. 3, 06.2013, p. 594-607.

Research output: Contribution to journalArticle

Potter, Michelle C. ; Figuera-Losada, Mariana ; Rojas, Camilo ; Slusher, Barbara S. / Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders. In: Journal of NeuroImmune Pharmacology. 2013 ; Vol. 8, No. 3. pp. 594-607.
@article{2266b019e7e840549ccf8bd1fc951e41,
title = "Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders",
abstract = "The accumulation of excess glutamate in the extracellular space as a consequence of CNS trauma, neurodegenerative diseases, infection, or deregulation of glutamate clearance results in neuronal damage by excessive excitatory neurotransmission. Glutamate excitotoxicity is thought to be one of several mechanisms by which HIV exerts neurotoxicity that culminates in HIV-associated neurocognitive disorders (HAND). Excess glutamate is released upon HIV infection of macrophage/microglial cells and has been associated with neurotoxicity mediated by gp120, transactivator of transcription (Tat) and other HIV proteins. Several strategies have been used over the years to try to prevent glutamate excitotoxicity. Since the main toxic effects of excess glutamate are thought to be due to excitotoxicity from over activation of glutamate receptors, antagonists of these receptors have been popular therapeutic targets. Early work to ameliorate the effects of excess extracellular glutamate focused on NMDA receptor antagonism, but unfortunately, potent blockade of this receptor has been fraught with side effects. One alternative to direct receptor blockade has been the inhibition of enzymes responsible for the production of glutamate such as glutaminase and glutamate carboxypeptidase II. Another approach has been to regulate the transporters responsible for modulation of extracellular glutamate such as excitatory amino acid transporters and the glutamate-cystine antiporter. There is preliminary experimental evidence that these approaches have potential therapeutic utility for the treatment of HAND. These efforts however, are at an early stage where the next steps are dependent on the identification of drug-like inhibitors as well as the development of predictive neuroAIDS animal models.",
keywords = "Excitotoxicity, Glutamate, Glutamate carboxypeptidase II, Glutaminase, HIV-associated neurocognitive disorder",
author = "Potter, {Michelle C.} and Mariana Figuera-Losada and Camilo Rojas and Slusher, {Barbara S.}",
year = "2013",
month = "6",
doi = "10.1007/s11481-013-9442-z",
language = "English (US)",
volume = "8",
pages = "594--607",
journal = "Journal of NeuroImmune Pharmacology",
issn = "1557-1890",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders

AU - Potter, Michelle C.

AU - Figuera-Losada, Mariana

AU - Rojas, Camilo

AU - Slusher, Barbara S.

PY - 2013/6

Y1 - 2013/6

N2 - The accumulation of excess glutamate in the extracellular space as a consequence of CNS trauma, neurodegenerative diseases, infection, or deregulation of glutamate clearance results in neuronal damage by excessive excitatory neurotransmission. Glutamate excitotoxicity is thought to be one of several mechanisms by which HIV exerts neurotoxicity that culminates in HIV-associated neurocognitive disorders (HAND). Excess glutamate is released upon HIV infection of macrophage/microglial cells and has been associated with neurotoxicity mediated by gp120, transactivator of transcription (Tat) and other HIV proteins. Several strategies have been used over the years to try to prevent glutamate excitotoxicity. Since the main toxic effects of excess glutamate are thought to be due to excitotoxicity from over activation of glutamate receptors, antagonists of these receptors have been popular therapeutic targets. Early work to ameliorate the effects of excess extracellular glutamate focused on NMDA receptor antagonism, but unfortunately, potent blockade of this receptor has been fraught with side effects. One alternative to direct receptor blockade has been the inhibition of enzymes responsible for the production of glutamate such as glutaminase and glutamate carboxypeptidase II. Another approach has been to regulate the transporters responsible for modulation of extracellular glutamate such as excitatory amino acid transporters and the glutamate-cystine antiporter. There is preliminary experimental evidence that these approaches have potential therapeutic utility for the treatment of HAND. These efforts however, are at an early stage where the next steps are dependent on the identification of drug-like inhibitors as well as the development of predictive neuroAIDS animal models.

AB - The accumulation of excess glutamate in the extracellular space as a consequence of CNS trauma, neurodegenerative diseases, infection, or deregulation of glutamate clearance results in neuronal damage by excessive excitatory neurotransmission. Glutamate excitotoxicity is thought to be one of several mechanisms by which HIV exerts neurotoxicity that culminates in HIV-associated neurocognitive disorders (HAND). Excess glutamate is released upon HIV infection of macrophage/microglial cells and has been associated with neurotoxicity mediated by gp120, transactivator of transcription (Tat) and other HIV proteins. Several strategies have been used over the years to try to prevent glutamate excitotoxicity. Since the main toxic effects of excess glutamate are thought to be due to excitotoxicity from over activation of glutamate receptors, antagonists of these receptors have been popular therapeutic targets. Early work to ameliorate the effects of excess extracellular glutamate focused on NMDA receptor antagonism, but unfortunately, potent blockade of this receptor has been fraught with side effects. One alternative to direct receptor blockade has been the inhibition of enzymes responsible for the production of glutamate such as glutaminase and glutamate carboxypeptidase II. Another approach has been to regulate the transporters responsible for modulation of extracellular glutamate such as excitatory amino acid transporters and the glutamate-cystine antiporter. There is preliminary experimental evidence that these approaches have potential therapeutic utility for the treatment of HAND. These efforts however, are at an early stage where the next steps are dependent on the identification of drug-like inhibitors as well as the development of predictive neuroAIDS animal models.

KW - Excitotoxicity

KW - Glutamate

KW - Glutamate carboxypeptidase II

KW - Glutaminase

KW - HIV-associated neurocognitive disorder

UR - http://www.scopus.com/inward/record.url?scp=84878784823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878784823&partnerID=8YFLogxK

U2 - 10.1007/s11481-013-9442-z

DO - 10.1007/s11481-013-9442-z

M3 - Article

C2 - 23553365

AN - SCOPUS:84878784823

VL - 8

SP - 594

EP - 607

JO - Journal of NeuroImmune Pharmacology

JF - Journal of NeuroImmune Pharmacology

SN - 1557-1890

IS - 3

ER -